Skip to content

Observation of the Efficacy of Percutaneous Auricular Vagus Nerve Stimulation Combined with Sphenopalatine Ganglion Block in Knee Osteoarthritis: A Randomized Controlled Trial

Observation of the Efficacy of Percutaneous Auricular Vagus Nerve Stimulation Combined with Sphenopalatine Ganglion Block in Knee Osteoarthritis: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118698
Enrollment
Unknown
Registered
2026-02-10
Start date
2026-02-15
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

Experimental group:Vagus nerve stimulation was applied 30 minutes after breakfast and 30 minutes after dinner at 25 Hz, 250 µs, with a current intensity of 0.25 mA to 2.0 mA. Each session lasted 30 mi
Control group:Vagus nerve stimulation was performed 30 minutes after breakfast and 30 minutes after dinner at 25 Hz, 250 µs, with a current intensity of 0.25 mA–2.0 mA, each session lasting 30 minutes

Sponsors

The Four Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: Aged 65-85, with normal heart, liver, and kidney function, normal consciousness, normal coagulation function, meeting the diagnostic criteria for knee osteoarthritis.

Exclusion criteria

Exclusion criteria: 1.Patients with a history of mental illness, neurological disorders, psychological disorders, allergy to local anesthetics, inability to communicate normally, or those taking antidepressants or anti-anxiety medications; 2.Patients who do not meet the diagnostic criteria for knee osteoarthritis.

Design outcomes

Primary

MeasureTime frame
Incidence of VAS=0 to VAS>=4 after 7 days of treatment in the two groups of patients;

Secondary

MeasureTime frame
VAS scores before nerve block (T0), on the third day of treatment (T1), on the fifth day of treatment (T2), one week after discharge (T3), four weeks after discharge (T4), and eight weeks after block (T5);Pittsburgh Sleep Quality Index;Total amount of tramadol taken during treatment;Anxiety Scale Score (S-AI);Adverse reactions: nausea, dizziness, etc.;

Countries

China

Contacts

Public ContactWang Yan

The Four Affiliated Hospital of Anhui Medical University

ch2004640029@fy.ahmu.edu.cn+86 138 5658 6040

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026